Greenwich LifeSciences (GLSI) stock price is $16.09, up 0.12% on the day, as of Nov 11, 2026. It has a market cap of $235.88Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap235.88 Mn
P/E-10.26
FCF (Yr)-9.91 Mn
ROA (Yr)-376.92
EV to EBIT-9.44
Net Income (Yr)-19.36 Mn
Enterprise Value206.51 Mn
Add ratio to table…
About
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of immunotherapy products for the treatment of cancer, with its primary focus on preventing breast cancer recurrence through its lead product candidate, GLSI-100.
The company generates revenue primarily through potential future commercialization of its product candidates, as it currently does not have any products approved for sale and is not generating revenue from product…
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of immunotherapy products for the treatment of cancer, with its primary focus on preventing breast cancer recurrence through its lead product candidate, GLSI-100.
The company generates revenue primarily through potential future commercialization of its product candidates, as it currently does not have any products approved for sale and is not generating revenue from product sales; its current activities are centered on clinical development and research.
The company operates through a single reportable segment focused on the research, development, and potential commercialization of its immunotherapy product candidates.
Greenwich LifeSciences, Inc. focuses its operations on the development of GLSI-100, which consists of the GP2 peptide combined with the immunoadjuvant GM-CSF, designed to elicit a targeted immune response against HER2/neu-expressing cancers, particularly for the prevention of breast cancer recurrence in patients who have completed standard trastuzumab-based therapy.
Greenwich LifeSciences, Inc. operates in the competitive field of cancer immunotherapy, where it faces large pharmaceutical companies with approved products and substantial resources, but believes its product candidate may offer a differentiated approach by targeting the HER2/neu antigen in combination with GM-CSF to stimulate a durable immune response in a specific patient population.
The company serves patients with HER2/neu-positive breast cancer who are at high risk of recurrence following surgery and standard adjuvant therapy, with its product candidate intended for use in clinical and hospital settings under physician supervision.
Sector:HealthcareSector rationaleThe company is a clinical-stage biopharmaceutical firm developing immunotherapy products, specifically GLSI-100 for the treatment of breast cancer. Its core business activity is the research and development of medical products for use in clinical and hospital settings, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryGreenwich LifeSciences is a clinical-stage biopharmaceutical company developing immunotherapy products, specifically GLSI-100, which utilizes the GP2 peptide and GM-CSF. These are biological components designed to elicit an immune response, fitting the description of therapies derived from biological science.Classified using BQ-MICSCIK: 0001799788
Peer percentiles
How Greenwich LifeSciences ranks
Ranked against the 695 companies in Pharmaceuticals and Biotechnology·58 metrics · as of Nov 11, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last